The NFKBIZ polymorphism (rs3217713) has been associated with the adalimumab response, and NFKBIZ-deletion-allele carriers are found at a significantly greater frequency among responders to adalimumab in the Caucasian population with psoriasis than among nonresponders (158). Here, NFKBIZ is linked to psoriasis.